COMPANY

Curza Inc

HQ: Salt Lake City, UT source · curza.com ↗ · Mountain

Location: Salt Lake City, UT · source · Oct 14, 2026

Profile checked Oct 10, 2026

14NIH grants

Funding and NIH signals

NIH award NIH awarded $1M (SBIR Phase II 5R44AI186898-03, continuation, notice Jun 26, 2026). NIH RePORTER 5R44AI186898-03 (Jun 26, 2026)
Evidence (1 event)
- Jun 26, 2026 · NIH RePORTER 5R44AI186898-03
  Organization: CURZA INC; City/State: Salt Lake City, UT; Project number: 5R44AI186898-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: New oral antibiotics focused on treating MDR Gram-negative infections; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 26, 2026 Grant Government grant — SBIR: $1M (annual award, as published), announced Jun 26, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 11, 2025 Grant Government grant — SBIR: $1M (annual award, as published), announced Aug 11, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jun 11, 2025 Grant Government grant — SBIR: $858,436 (annual award, as published), announced Jun 11, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 24, 2025 Grant Government grant — SBIR: $999,997 (annual award, as published), announced Apr 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Jun 26, 2026 Government grant — SBIR: $1M (annual award, as published), announced Jun 26, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 11, 2025 Government grant — SBIR: $1M (annual award, as published), announced Aug 11, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jun 11, 2025 Government grant — SBIR: $858,436 (annual award, as published), announced Jun 11, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Apr 24, 2025 Government grant — SBIR: $999,997 (annual award, as published), announced Apr 24, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 14

Annual award amounts. Total $12.7M.

Jul 9, 2024 NIH award 1R44AI186898-01 FY2024: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. New oral antibiotics focused on treating MDR Gra source ↗
Jun 11, 2024 NIH award 5R44AI170297-02 FY2024: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI SEBAHAR, PAUL; recipient as written: CURZA INC, Salt Lake City, UT. A New Class of Broad-Spectrum Antibacterial Agent source ↗
Apr 30, 2024 NIH award 1R44AI184155-01 FY2024: $999,998 awarded for that fiscal year; activity R44 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. A new class of antibiotic to address Antimicrobial source ↗
Jul 21, 2023 NIH award 1R44AI170297-01A1 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI SEBAHAR, PAUL; recipient as written: CURZA INC, Salt Lake City, UT. A New Class of Broad-Spectrum Antibacterial Age source ↗
Apr 15, 2022 NIH award 5R44AI152665-03 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. A new class of broad-spectrum antibacterials for source ↗
Jul 23, 2021 NIH award 5R01AI132304-05 FY2021: $1,045,564 awarded for that fiscal year; activity R01 (OTHER_NIH); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Broad spectrum antibacterials selectively t source ↗
Apr 2, 2021 NIH award 5R44AI152665-02 FY2021: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. A new class of broad-spectrum antibacterials for source ↗
Jun 3, 2020 NIH award 5R01AI132304-04 FY2020: $1,193,671 awarded for that fiscal year; activity R01 (OTHER_NIH); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Broad spectrum antibacterials selectively t source ↗
Apr 24, 2020 NIH award 1R44AI152665-01 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. A new class of broad-spectrum antibacterials for source ↗
Jun 14, 2019 NIH award 5R01AI132304-03 FY2019: $1,206,566 awarded for that fiscal year; activity R01 (OTHER_NIH); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Broad spectrum antibacterials selectively t source ↗
Jun 26, 2018 NIH award 5R01AI132304-02 FY2018: $766,731 awarded for that fiscal year; activity R01 (OTHER_NIH); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Broad spectrum antibacterials selectively tar source ↗
Jun 28, 2017 NIH award 5R43AI124821-02 FY2017: $298,770 awarded for that fiscal year; activity R43 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Natural product-inspired antibacterials with uniqu source ↗
Jun 20, 2017 NIH award 1R01AI132304-01 FY2017: $866,989 awarded for that fiscal year; activity R01 (OTHER_NIH); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Broad spectrum antibacterials selectively tar source ↗
Jun 22, 2016 NIH award 1R43AI124821-01A1 FY2016: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI TESTA, CHARLES; recipient as written: CURZA INC, Salt Lake City, UT. Natural product-inspired antibacterials with uni source ↗